Data as of Dec 19
| +0.64 / +3.97%|
The 5 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 25.00, with a high estimate of 34.00 and a low estimate of 15.00. The median estimate represents a +48.99% increase from the last price of 16.78.
The current consensus among 6 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.